Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivative for use in the treatment of cns disorders

[0054] If not otherwise specified or clear from context, the following terms as used herein have the following meetings:

[0055] “Alkyl” as used herein is a saturated or unsaturated hydrocarbon moiety, e.g., one to twenty-one carbon atoms in length, which may be linear or branched (e.g., n-butyl or tertbutyl), preferably linear, unless otherwise specified. For example, C1-21 alkyl denotes alkyl having 1 to 21 carbon atoms. In one embodiment, alkyl is optionally substituted with one or more hydroxy or C1-22alkoxy (e.g., ethoxy) groups. In another embodiment, alkyl contains 1 to 21 carbon atoms, preferably straight chain and optionally saturated or unsaturated, for example in some embodiments wherein Ri is an alkyl chain containing 1 to 21 carbon atoms, preferably 6-15 carbon atoms, 16-21 carbon atoms, e.g., so that together with the -C(O)- to which it attaches, e.g., when cleaved from the compound of Formula I, forms the residue of a natural or unnatural, saturated or unsaturated fatty acid.

[0056] The term “pharmaceutically acceptable diluent or carrier” is intended to mean diluents and carriers that are useful in pharmaceutical preparations, and that are free of substances that are allergenic, pyrogenic or pathogenic, and that are known to potentially cause or promote illness. Pharmaceutically acceptable diluents or carriers thus exclude bodily fluids such as example blood, urine, spinal fluid, saliva, and the like, as well as their constituent components such as blood cells and circulating proteins. Suitable pharmaceutically acceptable diluents and carriers can be found in any of several well-known

IT PCT treatises on pharmaceutical formulations, for example Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGrawHill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remington’s Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; and Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

[0057] The terms purified, in purified form or in isolated and purified form for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g., from a reaction mixture), or natural source or combination thereof. Thus, the term purified, in purified form or in isolated and purified form for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization, LC-MS and LC-MS/MS techniques and the like), in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.

[0058] The Compounds of Formula I, wherein Z is -(C=O)- or-(CH(OH))-, including for example the Compounds of Formulae II-B and II-C, may be produced as metabolites of a compound of Formula A, and/or as metabolites of a compound of Formula B:

<img file="IL260653A_D0001.tif" />

Formula A

IT PCT

<img file="IL260653A_D0002.tif" />

Formula B

The compound of Formula A is known to provide effective treatment of 5-HT2a, SERT and/or D2 receptor related disorders without significant extrapyramidal side effects, as similarly disclosed and claimed in WO 2009/145900, the contents of which are incorporated by reference in their entirety. The plasma levels of compounds of Formulas II-B and II-C produced from metabolism of a compound of Formula A are, however, quite low and probably do not contribute significantly to the therapeutic activity of the compound of Formula A. Compounds of Formulae II-D and II-E could also be present as metabolites, although this has so far not been detected. The Compounds of Formula I have unexpectedly been found to have activity as antagonists of the μ-opioid receptor. This is unexpected because the compound of Formula A has not been know or understood to have any μ-opioid receptor activity or binding. Compounds of Formula I wherein X is -NH- and wherein L is O- are shown to have particularly good μ-opioid receptor antagonism. Such Compounds of Formula I may therefore be useful in the treatment of drug dependency, such as opiate dependency and/or alcohol dependency, by inhibiting the endogenous opiate response to illicit drug administration, as well as by inhibiting the direct effects of ingestion of illicit opiate drugs.

[0059] It is surprising that metabolites of a compound of Formula A have somewhat different relative receptor binding affinity that compounds of Formula A. For example, the receptor binding profile of the compound for Formula II-B is very unique, with a combination of antagonist activities at 5-HT2A, Di and Mu opiate receptors, making this compound very interesting for treating mood disorders. The compound of Formula A is not active at the Mu opiate receptor, for example.

[0060] Unless otherwise indicated, the Compounds of the present disclosure, e.g., Compound I or 1.1-1.30, Compound II or 2.1-2.18, Compound ΠΙ or 3.1-3.13, or Compound IV or 4.1-4.13 (collectively, Compounds of Formulas I-IV et seq.) may exist in free or salt,

IT PCT

e.g., as acid addition salts, form. An acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, acid acetic, trifluoroacetic, citric, maleic acid, toluene sulfonic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmoic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic acid, and the like. In addition a salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)-amine. In a particular embodiment, the salt of the Compounds of the Invention is a toluenesulfonic acid addition salt. In another particular embodiment, the salt of the Compounds of the Invention is a fumaric acid addition salt. In a particular embodiment, the salt of the Compounds of the Invention is a phosphoric acid addition salt.

[0061] The Compounds of the present disclosure are intended for use as pharmaceuticals, therefore pharmaceutically acceptable salts are preferred. Salts which are unsuitable for pharmaceutical uses may be useful, for example, for the isolation or purification of free Compounds of the Invention, and are therefore also included.

[0062] The Compounds of the present disclosure may comprise one or more chiral carbon atoms. The compounds thus exist in individual isomeric, e.g., enantiomeric or diastereomeric form or as mixtures of individual forms, e.g., racemic/diastereomeric mixtures. Any isomer may be present in which the asymmetric center is in the (R)-, (5)-, or (R,S)- configuration. The invention is to be understood as embracing both individual optically active isomers as well as mixtures (e.g., racemic/diastereomeric mixtures) thereof. Accordingly, the Compounds of the Invention may be a racemic mixture or it may be predominantly, e.g., in pure, or substantially pure, isomeric form, e.g., greater than 70% enantiomeric/diastereomeric excess (“ee”), preferably greater than 80% ee, more preferably greater than 90% ee, most preferably greater than 95% ee. The purification of said isomers and the separation of said isomeric mixtures may be accomplished by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, simulated moving bed and the like).

IT PCT

[0063] Geometric isomers by nature of substituents about a double bond or a ring may be present in cis (Z) or trans (E) form, and both isomeric forms are encompassed within the scope of this invention.

[0064] It is also intended that the compounds of the present disclosure encompass their stable and unstable isotopes. Stable isotopes are nonradioactive isotopes which contain one additional neutron compared to the abundant nuclides of the same species (i.e., element). It is expected that the activity of compounds comprising such isotopes would be retained, and such compound would also have utility for measuring pharmacokinetics of the non-isotopic analogs. For example, the hydrogen atom at a certain position on the compounds of the disclosure may be replaced with deuterium (a stable isotope which is non-radioactive). Examples of known stable isotopes include, but not limited to, deuterium, 13C, 15N, 18O. Alternatively, unstable isotopes, which are radioactive isotopes which contain additional neutrons compared to the abundant nuclides of the same species (i.e., element), e.g., 123I, 131I, 125I, 11C, 18F, may replace the corresponding abundant species of I, C and F. Another example of useful isotope of the compound of the invention is the 11C isotope.

These radio isotopes are useful for radio-imaging and/or pharmacokinetic studies of the compounds of the invention. In addition, the substitution of atoms of having the natural isotopic distributing with heavier isotopes can result in desirable change in pharmacokinetic rates when these substitutions are made at metabolically liable sites. For example, the incorporation of deuterium (2H) in place of hydrogen can slow metabolic degradation when the position of the hydrogen is a site of enzymatic or metabolic activity.

[0065] In addition to the unique characteristic of the Compounds of the present disclosure, the Compounds of Formula I, wherein Y is -C(H)(0H)- may also be esterified to form physiologically hydrolysable and acceptable ester prodrugs. As used herein, “physiologically hydrolysable and acceptable esters” means esters of Compounds of the present disclosure which are hydrolysable under physiological conditions to yield hydroxy on the one hand and acid, e.g., carboxylic acid on the other, which are themselves physiologically tolerable at doses to be administered. For Example, the Compound of Formula I or Formula II wherein Y is -C(H)(0H) may be esterified to form a prodrug, i.e., a Compound of Formula I Formula II wherein Ri is -C(O)-C1-21 alkyl. In some preferred embodiments, Ri is -C(O)-C 1-21 alkyl, e.g., acyl acid esters, e.g., heptanoic, octanoic, decanoic, dodecanoic, tetradecanoic or hexadecanoic acid ester.

IT PCT

[0066] Similarly, wherein the Compounds of the present disclosure contain an amine group, prodrug of such amine, e.g., methyl amine prodrugs may also exist wherein the prodrug is cleaved to release the amine metabolite in vivo following administration.

[0067] The prodrugs of the Compounds of the present disclosure wherein Riis -C(O)C1-21 alkyl, preferably -C6-21 alkyl, more preferably C6-15alkyl, more preferably linear, saturated or unsaturated and optionally substituted with one or more hydroxy or alkoxy groups, are particularly useful for sustained- and/or delayed release so as to achieve a long acting effect, e.g., wherein the Compounds of the present disclosure is released over a period of from about 14 to about 30 to about 180 days, preferably over about 30 or about 60 or about 90 days, for example as described in any of depot composition as described herein.

Preferably, the sustained and/or delayed-release formulation is an injectable formulation. [0068] Alternatively and/or additionally, the Compounds of the present disclosure may be included as a depot formulation, e.g., by dispersing, dissolving or encapsulating the Compounds of the Invention in a polymeric matrix as described in any of Composition 6 and 6.1-6.10, such that the Compound is continually released as the polymer degrades over time. The release of the Compounds of the Invention from the polymeric matrix provides for the controlled- and/or delayed- and/or sustained-release of the Compounds, e.g., from the pharmaceutical depot composition, into a subject, for example a warm-blooded animal such as man, to which the pharmaceutical depot is administered. Thus, the pharmaceutical depot delivers the Compounds of the Invention to the subject at concentrations effective for treatment of the particular disease or medical condition over a sustained period of time, e.g., 14-180 days, preferably about 30, about 60 or about 90 days.

[0069] Polymers useful for the polymeric matrix in the Composition of the Invention (e.g., Depot composition of the Invention) may include a polyester of a hydroxyfatty acid and derivatives thereof or other agents such as polylactic acid, polyglycolic acid, polycitric acid, polymalic acid, poly-beta.-hydroxybutyric acid, epsilon.-capro-lactone ring opening polymer, lactic acid-glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, polylactic acid-polyethyleneglycol copolymer or polyglycolic acid-polyethyleneglycol copolymer), a polymer of an alkyl alpha-cyanoacrylate (for example poly(butyl 2cyanoacrylate)), a polyalkylene oxalate (for example polytrimethylene oxalate or polytetramethylene oxalate), a polyortho ester, a polycarbonate (for example polyethylene carbonate or polyethylenepropylene carbonate), a polyortho-carbonate, a polyamino acid (for example poly-gamma.-L-alanine, poly-.gamma.-benzyl-L-glutamic acid or poly-y-methyl-L

IT PCT glutamic acid), a hyaluronic acid ester, and the like, and one or more of these polymers can be used.

[0070] If the polymers are copolymers, they may be any of random, block and/or graft copolymers. When the above alpha-hydroxycarboxylic acids, hydroxydicarboxylic acids and hydroxytri carboxylic acids have optical activity in their molecules, any one of D-isomers, Lisomers and/or DL-isomers may be used. Among others, alpha-hydroxycarboxylic acid polymer (preferably lactic acid-glycolic acid polymer), its ester, poly-alpha-cyanoacrylic acid esters, etc. may be used, and lactic acid-glycolic acid copolymer (also referred to as poly(lactide-alpha-glycolide) or poly(lactic-co-glycolic acid), and hereinafter referred to as PLGA) are preferred. Thus, in one aspect the polymer useful for the polymeric matrix is PLGA. As used herein, the term PLGA includes polymers of lactic acid (also referred to as polylactide, poly(lactic acid), or PLA). Most preferably, the polymer is the biodegradable poly(d,l-lactide-co-glycolide) polymer.

[0071] In a preferred embodiment, the polymeric matrix of the invention is a biocompatible and biodegradable polymeric material. The term “biocompatible” is defined as a polymeric material that is not toxic, is not carcinogenic, and does not significantly induce inflammation in body tissues. The matrix material should be biodegradable wherein the polymeric material should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body. The products of the biodegradation should also be biocompatible with the body in that the polymeric matrix is biocompatible with the body. Particular useful examples of polymeric matrix materials include poly(glycolic acid), polyD,L-lactic acid, poly-L-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxonone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acidcaprolactone), polyanhydrides, and natural polymers including albumin, casein, and waxes, such as, glycerol mono- and distearate, and the like. The preferred polymer for use in the practice of this invention is dl(polylactide-co-glycolide). It is preferred that the molar ratio of lactide to glycolide in such a copolymer be in the range of from about 75:25 to 50:50.

[0072] Useful PLGA polymers may have a weight-average molecular weight of from about 5,000 to 500,000 daltons, preferably about 150,000 daltons. Dependent on the rate of degradation to be achieved, different molecular weight of polymers may be used. For a diffusional mechanism of drug release, the polymer should remain intact until all of the drug is released from the polymeric matrix and then degrade. The drug can also be released from the polymeric matrix as the polymeric excipient bioerodes.

IT PCT

[0073] The PLGA may be prepared by any conventional method, or may be commercially available. For example, PLGA can be produced by ring-opening polymerization with a suitable catalyst from cyclic lactide, glycolide, etc. (see EP0058481B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure).

[0074] It is believed that PLGA is biodegradable by means of the degradation of the entire solid polymer composition, due to the break-down of hydrolysable and enzymatically cleavable ester linkages under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid. Both lactic acid and glycolic acid are water-soluble, non-toxic products of normal metabolism, which may further biodegrade to form carbon dioxide and water. In other words, PLGA is believed to degrade by means of hydrolysis of its ester groups in the presence of water, for example in the body of a warm-blooded animal such as man, to produce lactic acid and glycolic acid and create the acidic microclimate. Lactic and glycolic acid are by-products of various metabolic pathways in the body of a warm-blooded animal such as man under normal physiological conditions and therefore are well tolerated and produce minimal systemic toxicity.

[0075] In another embodiment, the polymeric matrix useful for the invention may comprise a star polymer wherein the structure of the polyester is star-shaped. These polyesters have a single polyol residue as a central moiety surrounded by acid residue chains. The polyol moiety may be, e. g., glucose or, e. g., mannitol. These esters are known and described in GB 2,145,422 and in U. S. Patent No. 5,538,739, the contents of which are incorporated by reference.

[0076] The star polymers may be prepared using polyhydroxy compounds, e. g., polyol, e. g., glucose or mannitol as the initiator. The polyol contains at least 3 hydroxy groups and has a molecular weight of up to about 20,000 Daltons, with at least 1, preferably at least 2, e.g. , as a mean 3 of the hydroxy groups of the polyol being in the form of ester groups, which contain polylactide or co-polylactide chains. The branched polyesters, e. g., poly (d, 1lactide-co-glycolide) have a central glucose moiety having rays of linear polylactide chains. [0077] The depot compositions of the invention (e.g., Compositions 6 and 6.1-6.10, in a polymer matrix) as hereinbefore described may comprise the polymer in the form of microparticles or nanoparticles, or in a liquid form, with the Compounds of the Invention dispersed or encapsulated therein. “Microparticles” is meant solid particles that contain the Compounds of the Invention either in solution or in solid form wherein such compound is

IT PCT dispersed or dissolved within the polymer that serves as the matrix of the particle. By an appropriate selection of polymeric materials, a microparticle formulation can be made in which the resulting microparticles exhibit both diffusional release and biodegradation release properties.

[0078] When the polymer is in the form of microparticles, the microparticles may be prepared using any appropriate method, such as by a solvent evaporation or solvent extraction method. For example, in the solvent evaporation method, the Compounds of the Invention and the polymer may be dissolved in a volatile organic solvent (for example a ketone such as acetone, a halogenated hydrocarbon such as chloroform or methylene chloride, a halogenated aromatic hydrocarbon, a cyclic ether such as dioxane, an ester such as ethyl acetate, a nitrile such as acetonitrile, or an alcohol such as ethanol) and dispersed in an aqueous phase containing a suitable emulsion stabilizer (for example polyvinyl alcohol, PVA). The organic solvent is then evaporated to provide microparticles with the Compounds of the Invention encapsulated therein. In the solvent extraction method, the Compounds of the Invention and polymer may be dissolved in a polar solvent (such as acetonitrile, dichloromethane, methanol, ethyl acetate or methyl formate) and then dispersed in an aqueous phase (such as a water/PVA solution). An emulsion is produced to provide microparticles with the Compounds of the Invention encapsulated therein. Spray drying is an alternative manufacturing technique for preparing the microparticles.

[0079] Another method for preparing the microparticles of the invention is also described in both U.S. Pat. No. 4,389,330 and U.S. Pat. No. 4,530,840.

[0080] The microparticle of the present invention can be prepared by any method capable of producing microparticles in a size range acceptable for use in an injectable composition. One preferred method of preparation is that described in U.S. Pat. No. 4,389,330. In this method the active agent is dissolved or dispersed in an appropriate solvent. To the agentcontaining medium is added the polymeric matrix material in an amount relative to the active ingredient that provides a product having the desired loading of active agent. Optionally, all of the ingredients of the microparticle product can be blended in the solvent medium together.

[0081] Solvents for the Compounds of the Invention and the polymeric matrix material that can be employed in the practice of the present invention include organic solvents, such as acetone; halogenated hydrocarbons, such as chloroform, methylene chloride, and the like; aromatic hydrocarbon compounds; halogenated aromatic hydrocarbon compounds; cyclic ethers; alcohols, such as, benzyl alcohol; ethyl acetate; and the like. In one embodiment, the

IT PCT solvent for use in the practice of the present invention may be a mixture of benzyl alcohol and ethyl acetate. Further information for the preparation of microparticles useful for the invention can be found in U.S. Patent Publication Number 2008/0069885, the contents of which are incorporated herein by reference in their entirety.

[0082] The amount of the Compounds of the present disclosure incorporated in the microparticles usually ranges from about 1 wt % to about 90 wt. %, preferably 30 to 50 wt. %, more preferably 35 to 40 wt. %. By weight % is meant parts of the Compounds of the present disclosure per total weight of microparticle.

[0083] The pharmaceutical depot compositions may comprise a pharmaceuticallyacceptable diluent or carrier, such as a water miscible diluent or carrier.

[0084] Details of Osmotic-controlled Release Oral delivery System composition may be found in EP 1 539 115 (U.S. Pub. No. 2009/0202631) and WO 2000/35419, the contents of each of which are incorporated by reference in their entirety.

[0085] A therapeutically effective amount is any amount of the Compounds of the invention (for example as contained in the pharmaceutical depot) which, when administered to a subject suffering from a disease or disorder, is effective to cause a reduction, remission, or regression of the disease or disorder over the period of time as intended for the treatment. [0086] Dosages employed in practicing the present invention will of course vary depending, e.g. on the particular disease or condition to be treated, the particular Compound of the Invention used, the mode of administration, and the therapy desired. Unless otherwise indicated, an amount of the Compound of the Invention for administration (whether administered as a free base or as a salt form) refers to or is based on the amount of the Compound of the Invention in free base form (i.e., the calculation of the amount is based on the free base amount).

[0087] Compounds of the Invention may be administered by any satisfactory route, including orally, parenterally (intravenously, intramuscular or subcutaneous) or transdermally, but are preferably administered orally. In certain embodiment, the Compounds of the Invention, e.g., in depot formulation, is preferably administered parenterally, e.g., by injection.

[0088] In general, satisfactory results for Method 1 and 1.1-1.35, Method 2 and 2.1-2.20, and Method 3 and 3.1-3.40, or use of the Compounds of the present disclosure as hereinbefore described, e.g. for the treatment of a combination of diseases such as a combination of at least depression, psychosis, e.g., (1) psychosis, e.g., schizophrenia, in a patient suffering from depression; (2) depression in a patient suffering from psychosis, e.g.,

IT PCT schizophrenia; (3) mood disorders associated with psychosis, e.g., schizophrenia, or Parkinson's disease; (4) sleep disorders associated with psychosis, e.g., schizophrenia, or Parkinson's disease; and (5) substance addiction, substance use disorders and/or substanceinduced disorders, as set forth above are indicated to be obtained on oral administration at dosages of the order from about 1 mg to 100 mg once daily, preferably 2.5 mg-50 mg, e.g., 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg or 50 mg, once daily, preferably via oral administration.

[0089] Satisfactory results for Method 2 or 2.1-2.20 or use of the Compounds of the present disclosure as hereinbefore described, e.g. for the treatment of sleep disorder alone are indicated to be obtained on oral administration at dosages of the order from about 2.5mg5mg, e.g., 2.5mg, 3mg, 4mg or 5mg, of a Compound of the Invention, in free or pharmaceutically acceptable salt form, once daily, preferably via oral administration.

[0090] Satisfactory results for Method I-A or Method II-A, or any of 3.1 -3.40 are indicated to be obtained at less than lOOmg, preferably less than 50mg, e.g., less than 40mg, less than 30mg, less than 20mg, less than lOmg, less than 5mg, less than 2.5mg, once daily. Satisfactory results for Method II-A or any of 3.1 -3.40 are indicated to be obtained at less than 5mg, preferably less than 2.5mg.

[0091] For treatment of the disorders disclosed herein wherein the depot composition is used to achieve longer duration of action, the dosages will be higher relative to the shorter action composition, e.g., higher than l-100mg, e.g., 25mg, 50mg, lOOmg, 500mg, l,000mg, or greater than lOOOmg. Duration of action of the Compounds of the present disclosure may be controlled by manipulation of the polymer composition, i.e., the polymerdrug ratio and microparticle size. Wherein the composition of the invention is a depot composition, administration by injection is preferred.

[0092] The pharmaceutically acceptable salts of the Compounds of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Further details for the preparation of these salts, e.g., toluenesulfonic salt in amorphous or crystal form, may be found in and/or U.S. Provisional Appl. No. 61/036,069.

[0093] Pharmaceutical compositions comprising Compounds of the present disclosure may be prepared using conventional diluents or excipients (an example include, but is not

IT PCT limited to sesame oil) and techniques known in the galenic art. Thus oral dosage forms may include tablets, capsules, solutions, suspensions and the like.

Methods of Making the Compounds of the Invention:

[0094] The Compounds of the present disclosure wherein X is -NH- or -N(CH3)- and Y is -C(=O) may be prepared by reacting (6bR, 10aS) oxo-2,3,6b,9,10,10a-hexahydrolH,7H-pyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxaline or its 1-methyl analog with 4-chloro-4'fluorobutyrophenone, in accordance with Scheme 1 below:

<img file="IL260653A_D0003.tif" />

X = -NH- or -N(CH3)Scheme 1

<img file="IL260653A_D0004.tif" />

[0095] Compounds of the present disclosure wherein X is -NH- or -N(CH3)- and Y is CH(OH)- may be prepared by reacting the 4-((6bR,10aS) oxo-2,3,6b,9,10,10a-hexahydrolH,7H-pyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4-fluoro-phenyl)-butan-l-one produced in Scheme 1 (or its 1-methyl analog) with a reducing agent, in accordance with Scheme 2, below:

<img file="IL260653A_D0005.tif" />

Scheme 2

[0096] The reducing agent may be a metal hydride, e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, aluminum hydride, diisobutylaluminum hydride, preferably sodium borohydride. Further reagents for reduction of ketones may be found in Jerry March, Advanced Organic Chemistry, Reactions Mechanisms and Structures,

IT PCT

p. 910-911, (1992, John Wiley &amp; Sons, Inc.), Fourth Edition, the contents of which are incorporated by reference.

[0097] Isolation or purification of the diastereomers of the Compounds of the Invention may be achieved by conventional methods known in the art, e.g., column purification, preparative thin layer chromatography, preparative HPLC, crystallization, trituration, simulated moving beds and the like.

[0098] The Compounds of Formula I wherein Y is -CH(O-Ri)- and Ri is other than H can be prepared by several commonly used esterification methods such as alcoholysis of acyl halides, anhydrides or active esters. For example, The Compound of Formula I, wherein Ri is -C(O)-alkyl may be prepared by reacting:

(a) L-C(O)-C 1-21 alkyl, wherein L is a leaving group such as a halo group (for example, chloro or bromo), trifluoromethyl sulfonyl oxy (-OSO2CF3), tosyloxy (-O-S(O)2-C6H4-CH3), methylsulfonyloxy (-O-S(O)2-CH3), 1Hbenzo[d][l,2,3]triazol-l-yloxy or succinimidyloxy group, with (b) the Compound of Formula I wherein Y is -C(H)(OH), preferably in the presence of a base (e.g., diisopropylamine, triethyl amine or pyridine). For example L-C(O)-C 1-21 alkyl is an acetyl halide, decanoyl halide or heptanoyl halide, which may be prepared by reacting HO-C(O)-C 1-21 alkyl, e.g., with thionyl chloride, P(X’)3 or P(X’)5 wherein X’ is Cl or Br. Wherein L is tosyloxy-C(O)-C 1-21 alkyl or methylsulfonyloxyC(O)-C 1-21 alkyl, these compounds may be prepared by reacting HO-C(O)-C 1-21 alkyl with tosyl-chloride or mesyl-chloride, preferably in the presence of a base such as pyridine. Synthesis of the Compound of Formula II-A where Ri is other than H may be summarized in Scheme 3 below:

<img file="IL260653A_D0006.tif" />

O

Formula I wherein L is -O-;

Xis -NH-,-N(CH3)-or-O-;

Yis -CH(OH)Scheme 3

<img file="IL260653A_D0007.tif" />

Formula II-A

R! is C(=O)-alkyl

IT PCT

[0099] Alternatively, the synthesis of the compound of Formula II-A where Ri is other than H maybe achieved by reacting HO-C(O)-C 1-21 alkyl with (i) a compound of Formula I wherein Y is -C(H)(OH) in the presence of a base such as DIEPA and NEt3, and (ii) a dehydrating or coupling reagent such as 2-fluoro-l-ethyl pyridinium tetrafluoroborate (FEP), tetramethylfluoromamidinium hexafluorophosphate (TFFH) or l,l,3,3-bis(tetramethylene) chlorouronium hexafluorophosphate (PyClU).

[00100] Salts of the Compounds of the present disclosure may be prepared as similarly described in U.S. Pat. No. 6,548,493; 7,238,690; 6,552,017; 6,713,471; 7,183,282; U.S. RE39680; U.S. RE39679; and WO 2009/114181, the contents of each of which are incorporated by reference in their entirety.

[00101] Diastereomers of prepared compounds can be separated by, for example, HPLC using CHIRALPAK® AY-H, 5μ, 30x250mm at room temperature and eluted with 10% ethanol / 90% hexane / 0.1% dimethylethylamine. Peaks can be detected at 230 nm to produce 98-99.9%ee of the diastereomer.

Example 1: Synthesis of 4-((6bR,10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7Hpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4-fluoro-phenyl)-butan-l-one

<img file="IL260653A_D0008.tif" />

O

[00102] (6bR, 10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7Hpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxaline carboxylic acid ethyl ester (6.4 g, 21.2 mmol) is suspended in HBr acetic acid solution (64 mL, 33% w/w) at room temperature. The mixture is heated at 50 °C for 16 h. After cooling, and treatment with ethyl acetate (300 mL), the mixture is filtered. The filter cake is washed with ethyl acetate (300 mL), and then dried under vacuum. The obtained HBr salt is then suspended in methanol (200 mL), and cooled with dry ice in isopropanol. Under vigorous stirring, ammonia solution (10 mL, 7N in methanol) is added slowly to the suspension to adjust the pH of the mixture to 10. The obtained mixture is dried under vacuum without further purification to give crude (6bR,

IT PCT

10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7H-pyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxaline (8.0 g), which is used directly in the next step. MS (ESI) m/z 230.2 [M+H]+.

[00103] The crude (6bR, 10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7Hpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxaline (1.4 g) is dissolved in DMF (14 mL), and then KI (2.15 g) and 4-Chloro-4'-fluorobutyrophenone (2 mL) are added successively. The mixture is degassed with argon, followed by adding Λζ/V-diisopropyl ethyl amine(DIPE A, 2 mL). The mixture is heated at 78 °C for 2h. After cooling, the solvents are removed under reduced pressure. The dark brown residue is suspended in di chloromethane (100 mL) and then extracted with water (30 mL). The organic layer is separated, and dried over K2CO3. After filtration, the solvents are removed under reduced pressure. The obtained crude product is purified by silica gel column chromatography eluting with 0 - 10% of methanol in ethyl acetate containing 0.1% of 7N ammonia in methanol to yield 4-((6bR,10aS) oxo2,3,6b,9,10,10a-hexahydro-lH,7H-pyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4fluoro-phenyl)-butan-l-one as a light yellow solid (767 mg). 1H NMR (500 MHz, DMSO-t/6) δ 10.3 (s, 1H), 8.1 - 8.0 (m, 2H), 7.3 (dd, J= 8.86 Hz, 2H), 6.8 (d, J= 7.25 Hz, 1H), 6.6 (dd, J= 7.55 Hz, 1H), 6.6 (d, J= 7.74 Hz, 1H), 3.8 (d, J= 14.49 Hz, 1H), 3.3 - 3.3 (m, 1H), 3.2 3.2 (m, 1H), 3.1 -3.0(m, 1H), 3.0 (t, J= 6.88 Hz, 2H), 2.8 - 2.8 (m, 1H), 2.6 - 2.5 (m, 1H), 2.3-2.2 (m, 2H), 2.1-2.0 (m, 1H), 1.9-1.8 (m, 1H), 1.8 (t, J = 6.99 Hz, 2H), 1.6 (t, J= 11.25 Hz, 2H). MS (ESI) m/z 394.2 [M+H]+.

Example 2: Synthesis of 4-((6bR,10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7Hpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4-fluoro-phenyl)-butan-l-ol

<img file="IL260653A_D0009.tif" />

[0101] 4-((6bR,10aS) oxo-2,3,6b,9,10,10a-hexahydro-lH,7Hpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4-fluoro-phenyl)-butan-l-one (50 mg,

IT PCT

0.127 mmol) is dissolved in methanol (5 mL). Under stirring, NaBH4 (31 mg, 0.82 mmol) is added in batches. After the completion of the addition, the mixture is stirred at room temperature for 30 min. Methanol is evaporated under reduced pressure. The residue is dissolved in dichloromethane (10 mL) and then extracted with water (2 x 0.5 mL). The combined organic phase is dried over K2CO3. After filtration, the filtrate is concentrated under reduced pressure and then further dried under vacuum to give 4-((6bR,10aS) oxo2,3,6b,9,10,10a-hexahydro-lH,7H-pyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin yl)-l-(4fluoro-phenyl)-butan-l-ol as a pale yellow foamy solid (45 mg, yield 90%). 1H NMR (500 MHz, DMSO-t/6) δ 10.3 (s, 1H), 7.4 - 7.3 (m, 2H), 7.2 - 7.1 (m, 2H), 6.7 (d, J= 7.29 Hz, 1H), 6.7 - 6.6 (m, 1H), 6.6 (d, J= &amp;#906;ΠΑ Hz, 1H), 5.4 (s, 1H), 4.7 - 4.4 (m, 1H), 3.8 (d, J= 14.49 Hz, 1H), 3.3-3.3 (m, 1H), 3.3-3.2 (m, 1H), 3.2 - 3.1 (m, 1H), 2.8 - 2.7 (m, 1H), 2.6 -2.5 (m, 1H), 2.3-2.1 (m, 2H), 2.1 - 2.0 (m, 1H), 2.0 - 1.9 (m, 1H), 1.8-1.7 (m, 1H), 1.71.5 (m, 3H), 1.5-1.4 (m, 1H), 1.4-1.3 (m, 1H). MS (ESI) m/z 396.2 [M+H]+.

Example 3: Synthesis of (6bR,10aS) (3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10ahexahydro-lH-pyrido[3',4':4,5]pyrrolo[l,2,3&amp;#1470;de]quinoxalin-2(3H)-one

<img file="IL260653A_D0010.tif" />

[0102] A mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-lHpyrido[3',4':4,5]pyrrolo[l,2,3-de]quinoxalin-2(3H)-one (lOOmg, 0.436 mmol), 1-(3chloroproxy) fluorobenzene (100pL, 0.65 mmol) and KI (144mg, 0.87 mmol) in DMF (2 mL) is degassed with argon for 3 minutes and DIPEA (150 pL, 0.87 mmol) is added. The resulting mixture is heated to 78 °C and stirred at this temperature for 2 h. The mixture is cooled to room temperature and then filtered. The filter cake is purified by silica gel column chromatography using a gradient of 0 - 100% ethyl acetate in a mixture of methanol/7N NH3 in methanol (1 : 0.1 v/v) as an eluent to produce partially purified product, which is further

IT PCT purified with a semi-preparative HPLC system using a gradient of 0 - 60% acetonitrile in water containing 0.1% formic acid over 16 min to obtain the title product as a solid (50mg, yield 30%). MS (ESI) m/z 406.2 [M+l]+. 1H NMR (500 MHz, DMSO-ri6) δ 10.3 (s, 1H), 7.2 - 7.1 (m, 2H), 7.0 - 6.9 (m, 2H), 6.8 (dd, J= 1.03, 7.25 Hz, 1H), 6.6 (t, J= 7.55 Hz, 1H), 6.6 (dd, J = 1.07, 7.79 Hz, 1H), 4.0 (t, J= 6.35 Hz, 2H), 3.8 (d, J= 14.74 Hz, 1H), 3.3-3.2 (m, 3H), 2.9 (dd, J = 6.35, 11.13 Hz, 1H), 2.7 - 2.6 (m, 1H), 2.5 - 2.3 (m, 2H), 2.1 (t, J= 11.66 Hz, 1H), 2.0 (d, J= 14.50 Hz, 1H), 1.9-1.8 (m, 3H), 1.7 (t, J= 11.04 Hz, 1H).

Pharmacologic profile

[0103] As noted above, Compounds of the Disclosure have a unique pharmacologic profile, with binding to 5-HT2A, Di and mu opiate receptors.

[0104] For example, the compound of Example 3 possesses low nanomolar affinity for 5HT2a, Di and mu opiate receptors with Ki values of 8.3nM, 50nM and 1 InM, respectively. [0105] The pharmacological profile of the compound of Example 3 is explored using in vitro receptor binding and cell-based functional assays and in vivo tests of functional activity at 5-HT2A, Di, D2, and mu opiate receptors, including DOI-induced head twitch, morphineinduced hyperactivity, western blotting measurements of brain phosphoprotein levels (tyrosine hydroxylase and GluN2B), and blockade of morphine activity in the classical mouse tail flick assay of pain.

[0106] The compound of Example 3 exhibits oral activity and excellent metabolic stability in animals. Oral administration of the compound of Example 3 potently blocks DOI-induced head twitches in mice (EC50 = 0.23mg/kg, p.o.) indicating strong functional activity as a 5HT2a antagonist. The compound of Example 3 does not disrupt striatal dopamine neurotransmission at doses tested, as indicated by a lack of effect on striatal tyrosine hydroxylase, the rate-limiting enzyme of dopamine synthesis. The compound of Example 3 (0.3mg/kg, p.o.) displays potent morphine antagonism in vivo, blocking morphine-induced hyperactivity and morphine-induced analgesia in mice at dose levels comparable to its 5-HT2A receptor effects (i.e., O.lmg/kg and above, p.o.).

[0107] Further details of the pharmacologic profiles of the Compounds of the Disclosure is described in the following examples.

Example 4: Cellular and Nuclear Receptor Functional Assays

IT PCT

[0108] Cellular and Nuclear Receptor Functional Assays are performed on the compounds of Formula II-B and II-C according to the procedure of Wang, J.B. et al. (1994), FEBS Lett., 338:217-222. The compounds are tested at several concentrations to determine their IC50 or EC50. Cellular agonist effects are calculated as percent of control response to a known reference agonist for each target and cellular antagonist effect is calculated as a percent inhibition of control reference agonist response for each target.

[0109] The following assay is performed to determine the effect of the Compound of Formula II-B on the μ (MOP) (h) receptor:

<td> Assay (Receptor)</td><td> Source</td><td> Stimulus</td><td> Incubation</td><td> Measured Component</td><td> Detection Method</td>

<td> μ (MOP) (h) (agonist effect)</td><td> human recombinant (CHO cells)</td><td> none (0.3 μΜ DAMGO for control)</td><td> 10 min @ 37°C</td><td> cAMP</td><td> HTRF</td>

<td> μ (MOP) (h) (antagonist effect)</td><td> human recombinant (CHO cells)</td><td> DAMGO (20 nM)</td><td> 10 min @ 37°C</td><td> cAMP</td><td> HTRF</td>

[0110] For the antagonists, the apparent dissociation constants (Kb) are calculated using the modified Cheng Prusoff equation:

IC50

1+(A/EC50a) where A = concentration of reference agonist in the assay, and EC50a = EC 50 value of the reference agonist.

[0111] The compound of Formula II-B is found to have a μ (MOP) (h) (antagonist effect) with an IC50 of 1.3 x 106&amp;#1470;M; and a Kb of 1.4 x 107&amp;#1470;M; and the compound of Formula II-C is found to have an IC50 greater than 1 x 105&amp;#1470;, which was the highest concentration tested.

[0112] The results are expressed as a percent of control agonist response:

measured response ------------- X100 control response and as a percent inhibition of control agonist response:

IT PCT (measured response ---------------- x 100 control response obtained in the presence of the Compound of Formula II-B or II-C.

[0113] The EC50 values (concentration producing a half-maximal response) and IC50 values (concentration causing a half-maximal inhibition of the control agonist response) are determined by non-linear regression analysis of the concentration-response curves generated with mean replicate values using Hill equation curve fitting:

1+(C/C5O)&amp;#1524;« where Y = response, A = left asymptote of the curve, D = right asymptote of the curve, C = compound concentration, and C50= EC50 or IC50, and nH = slope factor. The analysis is performed using software developed in-house and validated by comparison with data generated by the commercial software SigmaPlot ® 4.0 for Windows ® (© 1997 by SPSS Inc.).

Example 5: Receptor Binding Profile of Compound of Formulas II-B and II-C

[0114] Receptor binding is determined for the Compounds of Formulas II-A and II-B and Example 3, using the tosylate salt of the compound of Formula A as a control. The following literature procedures are used, each of which reference is incorporated herein by reference in their entireties: 5-HT2a: Bryant, H.U. et al. (1996), Life Sci., 15:1259-1268; D2: Hall, D.A. and Strange, P.G. (1997), Brit. J. Pharmacol., 121:731-736; DI: Zhou, Q.Y. et al. (1990), Nature, 347:76-80; SERT: Park, Y.M. et al. (1999), Anal. Biochem., 269:94-104; Mu opiate receptor: Wang, J.B. etal. (1994), FEBSLett., 338:217-222.

[0115] In general, the results are expressed as a percent of control specific binding:

measured specific binding ------------------- xlOO control specific binding and as a percent inhibition of control specific binding:

(measured specific binding \

------—------ xlOO control specific binding I obtained in the presence of the test compounds.

IT PCT

[0116] The IC50 values (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficients (nH) are determined by non-linear regression analysis of the competition curves generated with mean replicate values using Hill equation curve fitting:

A-D l+(C/C,&amp;#1524;) where Y = specific binding, A = left asymptote of the curve, D = right asymptote of the curve, C = compound concentration, C50 = IC50, and nH = slope factor. This analysis was performed using in -house software and validated by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). The inhibition constants (Ki) were calculated using the Cheng Prusoff equation:

(1+L^d) where L = concentration of radioligand in the assay, and Kd = affinity of the radioligand for the receptor. A Scatchard plot is used to determine the Kd.

[0117] The following receptor affinity results are obtained, using the tosylate salt of a

Compound of Formula A as a control:

<td> Receptor</td><td> Formula II-B (Ex. 1)</td><td> Formula II-C (Ex. 2)</td><td> Example 3</td><td> Formula A (tosylate salt)</td>

<td></td><td></td><td colspan="3"> Ki (nM) or maximum inhibition</td>

<td> 5-HT2A</td><td> 11</td><td> 31% inhibition at 240nM</td><td> 8.3</td><td> 10</td>

<td> D2</td><td> 47% inhibition at 240nM</td><td> 11% inhibition at 240nM</td><td> 160</td><td> 49</td>

<td> DI</td><td> 22</td><td> 13% inhibition at lOOnM</td><td> 50</td><td> 41</td>

<td> SERT</td><td> 44% inhibition at 240nM</td><td> No inhibition seen</td><td> 590</td><td> 16</td>

<td> Mu opiate receptor</td><td> 22</td><td> 85</td><td> 11</td><td> &gt;10,000</td>

Example 6: DOI-induced Head Twitch Model in Mice

[0118] R-(-)-2,5-dimethoxy iodoamphetamine (DOI) is an agonist of the serotonin 5HT2 receptor family. When administered to mice, it produces a behavioral profile associated with frequent head twitches. The frequency of these head twitches during a predetermined

IT PCT period of time can be taken as an estimate of 5-HT2 receptor agonism in the brain. Conversely, this behavioral assay can be used to determine 5-HT2 receptor antagonism in the brain by administering the DOI with or without an antagonist and recording the reduction in DOI-induced head twitches after the administration of the antagonist.

[0119] The method of Darmani et al., PharmacolBiochem Behav. (1990) 36:901-906 (the contents of which are incorporated by reference in their entirety) is used with some modifications. (±)-DOI HC1 is injected subcutaneously and the mice are immediately placed in a conventional plastic cage. The number of head twitches is counted during 6 min, beginning 1 min after DOI administration. The tested compound is administered orally 0.5 hr before the injection of DOI. Results area calculated as the EC50 for reducing DOI-induced head twitches. The results are shown in the following Table:

<td> Compound</td><td> EC50 (mg/kg, p.o.)</td>

<td> Example 1 (Formula II-B)</td><td> 0.23</td>

<td> Example 2 (Formula II-C)</td><td> 2.03</td>

<td> Example 3</td><td> 0.44</td>

<td> Formula A</td><td> 0.09</td>

<td> Formula B</td><td> 0.31</td>

The results show that the compounds of Example 1 and 3 potently block DOI head twitch, comparable to the reference compounds Formula A and C, and consistent with the in vitro 5HT2a results shown in Example 5. In contrast, the compound of Example 2 is relatively weaker in this functional assay, consistent with the in vitro data in Example 5 showing that this compound is relatively weaker in its serotonin receptor (5-HT2A ) antagonism compared to other structurally similar compounds.

Example 7: Mouse Tail Flick Assay

[0120] The Mouse Tail Flick Assay is a measure of an analgesia, indicated by the pain reflex threshold of restrained mice. Male CD-I mice are positioned with their tails under a focused beam of high-intensity infrared heat source, resulting in heating of the tail. The amount of time (latency) between turning on heating instrument and the flicking of the mouse’s tail out of path of the heat source is recorded. Administration of morphine results in analgesia, and this produces a delay in the mouse’s reaction to the heat (increased latency). Prior administration of a morphine antagonist, i.e., naloxone, reverses the effect and results in normal latency time. This test is used as a functional assay to gauge antagonism of mu-opiate

IT PCT receptors.

[0121] Ten male CD-I mice (about 8 weeks of age) are assigned to each of five treatment groups. The groups are treated as follows: Group (1) [negative control]: administered 0.25% methylcellulose vehicle p.o., 60 minutes before the tail flick test, and saline vehicle 30 minutes before the tail flick test; Group (2) [positive control]: administered 0.25% methylcellulose vehicle p.o., 60 minutes before the test, and 5 mg/kg morphine in saline 30 minutes before the test; Group (3) [positive control]: administered 3 mg/kg naloxone in saline 50 minutes before the test, and 5 mg/kg morphine in saline 30 minutes before the test; Groups (4)-(6): administered either 0.1 mg/kg, 0.3 mg/kg or 1 mg/kg of the test compound in 0.25% methylcellulose vehicle p.o., 60 minutes before the test, and 5 mg/kg morphine in 30 minutes before the test. The experiment is repeated for the compounds of Example 1 and Example 3. The results are shown in the following table as mean latency measured in seconds:

<td></td><td> Group 1 Veh/Veh</td><td> Group 2 Veh/Mor</td><td> Group 3 Nal/Mor</td><td> Group 4 Cmpd/Mor (0.1 mg/kg)</td><td> Group 5 Cmpd/Mor (0.3 mg/kg)</td><td> Group 6 Cmpd/Mor (1 mg/kg)</td>

<td> Ex. 1</td><td> 1.028</td><td> 9.361</td><td> 2.496</td><td> 8.870</td><td> 6.907</td><td> 6.240</td>

<td> Ex. 3</td><td> 0.887</td><td> 8.261</td><td> 3.013</td><td> 6.947</td><td> 5.853</td><td> 6.537</td>

[0122] The results demonstrate that the compounds of Example and Example 3 both exert a dose-dependent blockade of morphine-induced mu-opiate receptor activity.

Example 8: CNS Phosphoprotein Profile

[0123] A comprehensive molecular phosphorylation study is also carried out to examine the central nervous system (CNS) profile of the compounds of Example 1 and Example 3. The extent of protein phosphorylation for selected key central nervous system proteins is measured in mice nucleus accumbens. Examined proteins include ERK1, ERK2, Glul, NR2B and TH (tyrosine hydroxylase), and the compounds of Example 1 and 3 were compared to the antipsychotic agents risperidone and haloperidol.

[0124] Mice were treated with the compound of Example 1 or 3 at 3 mg/kg, or with haloperidol at 2 mg/kg. Mice were killed 30 minutes to 2 hours post-injection by focused microwave cranial irradiation, which preserves brain phosphoprotein as it exists at the time of death. Nucleus accumbens was then dissected from each mouse brain, sliced and frozen in liquid nitrogen. Samples were further prepared for phosphoprotein analysis via SDS-PAGE electrophoresis followed by phosphoprotein-specific immunoblotting, as described in Zhu H, et al., Brain Res. 2010 Jun 25; 1342:11-23. Phosphorylation at each site was quantified,

IT PCT normalized to total levels of the protein (non-phosphorylated), and expressed as percent of the level of phosphorylation in vehicle-treated control mice.

[0125] The results demonstrate that neither the compound of Example 1 nor of Example 3 has a significant effect on tyrosine hydroxylase phosphorylation at Ser40 at 30 minutes or 60 minutes, in contrast to haloperidol which produces a greater than 400% increase, and risperidone which produces a greater than 500% increase, in TH phosphorylation. This demonstrates that the inventive compounds do not disrupt dopamine metabolism.

[0126] The results further demonstrate that neither the compound of Example 1 nor of Example 3 has a significant effect on NR2B phosphorylation at Tyrl472 at 30-60 minutes. The compounds produce a slight increase in GluRl phosphorylation at Ser845, and a slight decrease in ERK2 phosphorylation at Thrl83 and Tyrl85.